All In Biotech

Drug Trial Radar · NCT02699099

Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.

Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever Vaccines Followed by a Booster of the Malaria Vaccine.

Last checked: Nov 19, 2026Latest source record: Sep 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 699 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

699

Actual

Start

May 10, 2017

Primary completion

Mar 14, 2018

Study completion Oct 7, 2020

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Mar 4, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 months, up to 6 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the immunogenicity, safety, and reactogenicity of the SB257049 candidate malaria vaccine when co-administered with Vitamin A, measles, rubella and yellow fever vaccines to children aged 6 months at the first vaccination.

Conditions

  • Malaria
  • Malaria Vaccines

Interventions

  • Vitamin ADietary supplement

    Oral administration of Vitamin A (1 dose)

  • Candidate Plasmodium falciparum malaria vaccineBiological

    Intramuscular administration of SB257049 vaccine (4 doses)

  • MR-VacBiological

    Subcutaneous injection of a combined measles and rubella vaccine (1 dose)

  • StamarilBiological

    Intramuscular injection of a yellow fever (YF) vaccine (1 dose)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Anti-Circumsporozoite (Anti-CS) Antibody Concentrations, One Month Post Dose 3 of SB257049 (Primary Analysis)Time frame: At one month post Dose 3 of SB257049 (Month 4)
  2. Anti-CS Antibody Concentrations, One Month Post Dose 3 of SB257049 (Study End Analysis)Time frame: At one month post Dose 3 of SB257049 (Month 4)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Kintampo, Ghana

  • GSK Investigational Site

    Kumasi, Ghana

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.